The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Stocks•22 April 2026•

1 min read

Senzime Q1 Results Show Improved Cash Flow Despite Slight Sales Dip

Golden bull statue and US flag over a New York City skyline with Dow Jones chart showing a decline, Bitcoin, and other financial data.

Key Facts

1Net sales amounted to SEK 23,233 thousand, representing a 1% decrease year-over-year.

2Currency-adjusted net sales increased by 11%, while US market sales decreased by 5%.

3Gross margin before depreciation stood at 63.1% compared to 65.9% in the prior period.

Senzime AB reported its Q1 2026 interim results, revealing net sales of SEK 23,233 thousand, a marginal 1% decrease compared to the previous year. However, currency-adjusted net sales demonstrated underlying strength with an 11% increase, highlighting robust demand despite foreign exchange headwinds. The US market faced challenges, with sales declining by 5%, which contributed to the slight dip in nominal revenue. Gross margin before depreciation compressed to 63.1% from 65.9% in the prior period, reflecting shifts in the product mix. Despite these mixed signals, management maintained its full-year targets, bolstered by improved cash flow and reduced operating expenses. Market participants are now focusing on the company's ability to regain growth momentum in the critical US healthcare sector.